Assenagon Asset Management S.A. Takes $4.08 Million Position in Medpace Holdings, Inc. $MEDP

Key Points

• Assenagon Asset Management S.A. opened a new position in Medpace Holdings (NASDAQ:MEDP) in Q4, buying 7,272 shares valued at about $4.08 million.
• Medpace beat quarterly expectations with EPS $4.67 vs. $4.18 and revenue of $708.45M (up 32% YoY), and set FY2026 EPS guidance of 16.68–17.50.
• Company President Jesse J. Geiger sold 31,707 shares for roughly $14.44M, while institutional investors own about 77.98% of the stock and analysts' consensus is a "Hold" with a $486.67 price target.

Assenagon Asset Management S.A. acquired a new position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 7,272 shares of the company's stock, valued at approximately $4,084,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. AQR Capital Management LLC grew its position in shares of Medpace by 65.1% in the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company's stock valued at $518,170,000 after buying an additional 404,226 shares during the last quarter. Wasatch Advisors LP raised its holdings in Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company's stock worth $296,853,000 after purchasing an additional 116,354 shares during the last quarter. Baillie Gifford & Co. lifted its position in shares of Medpace by 12.0% in the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company's stock worth $300,679,000 after purchasing an additional 62,503 shares during the period. Invesco Ltd. lifted its position in shares of Medpace by 18.9% in the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company's stock worth $276,313,000 after purchasing an additional 85,517 shares during the period. Finally, Epoch Investment Partners Inc. boosted its stake in shares of Medpace by 11.4% in the 2nd quarter. Epoch Investment Partners Inc. now owns 445,231 shares of the company's stock valued at $139,740,000 after purchasing an additional 45,435 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Performance

NASDAQ:MEDP opened at $451.20 on Monday. The stock has a market capitalization of $12.81 billion, a price-to-earnings ratio of 29.49, a PEG ratio of 2.16 and a beta of 1.44. The firm has a fifty day simple moving average of $494.07 and a two-hundred day simple moving average of $537.84. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $628.92.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. During the same quarter in the prior year, the business earned $3.67 earnings per share. The business's quarterly revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Activity

In related news, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the sale, the president owned 15,000 shares of the company's stock, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 20.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on MEDP shares. Wall Street Zen upgraded shares of Medpace from a "hold" rating to a "buy" rating in a research report on Saturday, January 17th. BMO Capital Markets reaffirmed a "market perform" rating on shares of Medpace in a research report on Wednesday, February 11th. Barclays upgraded Medpace from an "underweight" rating to an "equal weight" rating and set a $500.00 price target for the company in a report on Friday, March 6th. TD Cowen raised Medpace from a "sell" rating to a "hold" rating and dropped their price objective for the company from $462.00 to $419.00 in a research note on Wednesday, February 18th. Finally, Robert W. Baird upgraded Medpace from a "neutral" rating to an "outperform" rating and set a $564.00 target price on the stock in a research report on Tuesday, February 10th. Five equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $486.67.

Medpace Company Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.